Pyxis Oncology (PYXS) Asset Utilization Ratio (2024 - 2026)
Pyxis Oncology's (PYXS) quarterly Asset Utilization Ratio came in at 0.19 in Q2 2026, up 769.41% year-over-year from 0.02 in Q2 2025, and up 34.61% quarter-over-quarter from 0.14 in Q4 2025.
Analysis
Pyxis Oncology (PYXS) Asset Utilization Ratio (2024 - 2026) Analysis & Trends
Pyxis Oncology (PYXS) has reported Asset Utilization Ratio for 3 consecutive years, with 0.19 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Asset Utilization Ratio rose 769.41% year-over-year to 0.19 in Q2 2026; TTM through Jun 2026 was 0.19, a 769.41% increase from a year earlier, with the FY2025 full-year figure at 0.11, up 14.2% from the prior year.
- Asset Utilization Ratio was 0.19 for Q2 2026 at Pyxis Oncology, up from 0.14 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.19 in Q2 2026 and troughed at 0.02 in Q2 2025.
- A 3-year average of 0.09 and a median of 0.09 in 2024 frame the typical range for Asset Utilization Ratio.
- Across the five-year window, Asset Utilization Ratio soared 53.48% in 2025 and surged 769.41% in 2026, its largest moves.
- Over 3 years, Asset Utilization Ratio stood at 0.09 in 2024, then soared by 53.48% to 0.14 in 2025, then surged by 34.61% to 0.19 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.19 (Q2 2026), 0.14 (Q4 2025), and 0.02 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 0.40 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 0.58 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 0.47 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 0.38 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 0.20 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 0.90 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 0.33 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 0.00 |
| 10 | Pyxis Oncology | 208.61 Mn | 175.62 Mn | - | 0.19 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.19 |
| Dec 31, 2025 | 0.14 |
| Sep 30, 2025 | 0.02 |
| Jun 30, 2025 | 0.02 |
| Dec 31, 2024 | 0.09 |